Full Press Release Details
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia.
ARGX
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
Key Takeaway: argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia